Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tg Therapeutics (TGTX) Shares Outstanding (Weighted Average) (2016 - 2025)

Tg Therapeutics (TGTX) has 9 years of Shares Outstanding (Weighted Average) data on record, last reported at $146.2 million in Q1 2024.

  • For Q1 2024, Shares Outstanding (Weighted Average) rose 4.2% year-over-year to $146.2 million; the TTM value through Mar 2024 reached $146.2 million, up 4.2%, while the annual FY2022 figure was $135.4 million, 2.41% up from the prior year.
  • Shares Outstanding (Weighted Average) reached $146.2 million in Q1 2024 per TGTX's latest filing, up from $141.5 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $146.2 million in Q1 2024 and bottomed at $105.5 million in Q1 2020.
  • Average Shares Outstanding (Weighted Average) over 5 years is $129.9 million, with a median of $132.4 million recorded in 2021.
  • Peak YoY movement for Shares Outstanding (Weighted Average): surged 33.75% in 2020, then rose 1.9% in 2022.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $115.3 million in 2020, then rose by 14.64% to $132.2 million in 2021, then grew by 2.41% to $135.4 million in 2022, then rose by 4.5% to $141.5 million in 2023, then rose by 3.33% to $146.2 million in 2024.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding (Weighted Average) were $146.2 million in Q1 2024, $141.5 million in Q2 2023, and $140.3 million in Q1 2023.